Type 2 Diabetes Clinical Trial
Official title:
High-amylose Barley (HIAMBA) in the Regulation and Prevention of Type 2 Diabetes: a Randomized, Cross-over, Acute Dietary Intervention Study.
In a series of double-blinded randomized cross-over acute studies, the investigators want to study the effects of naturally produced high-amylose barley (Lean-baking barley®) on the postprandial glucose-metabolism in subjects with and without type 2 diabetes (T2D).
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | December 31, 2024 |
Est. primary completion date | July 1, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria for T2D group: - T2D defined by standard Danish guidelines. - HbA1c between 42-78 mmol/l. - Treatment with drugs for hypertension and high cholesterol is allowed if the treatment dose is stable and does not demand changes during the study period. - Participants are encouraged to maintain their present psychical activity level and their smoking and alcohol habits. Exclusion Criteria: - Type 1 diabetes - Insulin demanding T2D - Use of weekly administrated GLP-1 antagonist (e.g. ozempic, trulicity or byetta) - Use of acarbose - Significant cardiovascular, kidney, liver or endocrine comorbidity - Significant psychiatric history - Treatment with steroids - Alcohol or drug abuse - Pregnancy or breastfeeding - Legally incompetent |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Aarhus | Innovation Fund Denmark |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Postprandial glycemic response | Postprandial glycemic response Area under the curve for glucose (mmol/L) | Time Frame: Change from -10 minutes to 240 minutes after bread intake (measured at time -10,0,10,20,30,45,60,90,120,150,180,210,240 minutes) | |
Secondary | Postprandial insulin response | Area under the curve for insulin (pmol/L) | Change from -10 minutes to 240 minutes after bread (measured at time -10,0,10,20,30,45,60,90,120,150,180,210,240 minutes) | |
Secondary | Postprandial glucagon response | Area under the curve for glucagon (pg/mL) | Change from -10 minutes to 240 minutes after bread (measured at time -10,0,10,20,30,45,60,90,120,150,180,210,240 minutes) | |
Secondary | Postprandial triglyceride response | Area under the curve for triglyceride (mmol/L) | Change from -10 minutes to 240 minutes after bread (measured at time -10,0,30,60,120,180,240 minutes) | |
Secondary | Postprandial free fatty acid response | Area under the curve for free fatty acids (mmol/L) | Change from -10 minutes to 240 minutes after bread (measured at time -10,0,30,60,120,180,240 minutes) | |
Secondary | Postprandial GLP-1 (glucagon-like peptide-1) response | Area under the curve for GLP-1 (pmol/L) | Change from -10 minutes to 240 minutes after bread (measured at time -10,0,30,60,120,180,240 minutes) | |
Secondary | Postprandial GIP (Glucose-dependent insulinotropic polypeptide) response | Area under the curve for GIP (pmol/L) | Change from -10 minutes to 240 minutes after bread (measured at time -10,0,30,60,120,180,240 minutes) | |
Secondary | Visual analogue scale (VAS) | VAS-score of a number of standardized questions regarding, hunger, satiety, the test meal experience etc. Each answer is ranged on a 100 mm line expressing the most positive and negative rating possible at each end. | Measured at time 0,30,60,90,120,150,180,210,240 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |